文献速递炎症性肠病

综述:优化炎症性肠病中生物制剂(单克隆抗体)治疗应答

Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2024-01-01

该综述聚焦炎症性肠病中生物制剂(单克隆抗体)治疗的应答优化策略,包括治疗药物监测(TDM)的应用。TDM通过测定生物制剂血清浓度和检测中和性抗体来增强疗效;反应性TDM用于未达治疗目标时。TNF抑制剂最常与免疫原性和失应答相关;避免低血清药物浓度可减少免疫原性。非TNF抑制剂暴露-反应关系较弱,TDM的获益可能不如TNF抑制剂。

要点

  • 反应性TDM用于未达治疗目标时,指导剂量优化或换药。
  • 避免低血清药物浓度可减少TNF抑制剂的免疫原性。
  • 非TNF抑制剂暴露-反应关系较弱,TDM获益可能不如TNF抑制剂。

核心结论

  • 在达标治疗模式下,通过剂量优化(可能包括TDM)优化疗效可提高临床缓解的可能性,并可能实现超越症状控制的更深缓解。

研究设计与样本

  • 对已发表文献的广泛综述。

主要发现

  • TDM通过测定生物制剂血清浓度和检测中和性抗体,旨在增强暴露-反应关系可变药物的有效性。
  • 反应性TDM在未达治疗目标时进行。
  • TNF抑制剂是最常与免疫原性和失应答相关的治疗类别。
  • 避免低血清药物浓度(通过剂量优化或联用免疫调节剂)可减少免疫原性。
  • 无抗药抗体时的亚治疗剂量最好通过剂量递增或缩短给药间隔管理;持续中和性药物抗体需换用替代治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are a plethora of therapeutic options for the management of inflammatory bowel disease (IBD). Despite this, clinical outcomes with standard dosing often fall short of established targets. While efforts centre on developing novel therapies, there is an ongoing need to optimise the use of existing agents. AIMS: To focus on strategies to optimise response to biologic (monoclonal antibody) therapies in IBD, including use of therapeutic drug monitoring (TDM). METHODS: An extensive review of the published literature. RESULTS: TDM is a strategy aimed at enhancing the effectiveness of drugs with variable exposure-response relationships by measuring serum concentrations of biologic therapies and detecting neutralising antibodies. Reactive TDM is performed when therapeutic goals have not been achieved. Tumour necrosis factor alpha (TNF) inhibitors are the treatment class most frequently associated with immunogenicity and loss of response. Immunogenicity can be reduced through avoidance of low serum drug concentrations by dose optimisation or use of concomitant immunomodulator therapy. Subtherapeutic dosing in the absence of antidrug antibodies is best managed by dose escalation or dose interval reduction. Persistent neutralising drug antibodies necessitate switching to an alternative therapy. Proactively ensuring adequate serum trough levels might help sustain treatment durability and prevent loss of response. Newer non-TNF inhibitors demonstrate less robust exposure-response relationships, and TDM may not prove as beneficial. CONCLUSIONS: In the treat-to-target paradigm of IBD treatment, optimising treatment effect with dose optimisation, which may involve strategies including TDM, increases the likelihood of achieving clinical remission and may accomplish deeper levels of remission beyond symptom control.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chaemsupaphan T, Leong RW, Vande Casteele N, et al. Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease. Aliment Pharmacol Ther. 2024. PMID: 39403056. doi:10.1111/apt.18228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。